# APG101 in Myelodysplastic Syndrome

> **NCT01736436** · PHASE1 · COMPLETED · sponsor: **Apogenix GmbH** · enrollment: 20 (actual)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Treatment with APG101
- **PROCEDURE:** Bone marrow collection
- **PROCEDURE:** Blood drawings

## Key facts

- **NCT ID:** NCT01736436
- **Lead sponsor:** Apogenix GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2016-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01736436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01736436, "APG101 in Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01736436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*